Cancer Monoclonal Antibodies Market Report 2026

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $86.23 billion in 2025 to $98.11 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to limited availability of monoclonal antibody therapies, reliance on traditional chemotherapy, growing incidence of breast and blood cancers, increasing physician awareness of targeted therapies, expansion of hospital oncology departments.

The cancer monoclonal antibodies market size is expected to see rapid growth in the next few years. It will grow to $166.92 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to launch of novel immuno-oncology monoclonal antibodies, development of combination therapies, increasing adoption of personalized cancer treatment approaches, growth in research laboratory capabilities, rising investment in clinical trials and biologics manufacturing. Major trends in the forecast period include rising adoption of targeted monoclonal antibody therapies for various cancers, increasing investment in immuno-oncology research and development, expansion of personalized and precision cancer treatment programs, growth in hospital and research laboratory infrastructure for cancer therapy, integration of combination therapies and novel biologics in cancer treatment.

The global uptick in cancer cases is poised to drive expansion in the cancer monoclonal antibody market. Cancer comprises disorders where rogue cells multiply wildly, infiltrate tissues, and metastasize. This rising burden largely traces to aging demographics, since advanced age ranks as the top risk for most cancers, with most diagnoses striking those over 65. Cancer monoclonal antibody therapies advance treatment by locking onto tumor-specific markers, halting cell proliferation, marking cancers for immune attack, shuttling toxins straight to tumors, and reshaping the tumor setting to amplify natural anti-cancer defenses. For instance, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, recorded Australian cancer diagnoses climbing from 160,570 in 2022 to 164,694 in 2023, signaling a clear yearly surge. Globally, lung, prostate, bowel, and female breast cancers claim 43% of new cases. Therefore, the climb in global cancer rates is set to heighten demand and growth in the cancer monoclonal antibody market.

Prominent companies in the cancer monoclonal antibodies market are pioneering oncology innovations like bispecific antibody technology to direct T-cells against malignant B-cells. Bispecific antibody technology crafts antibodies grabbing two targets at once, sparking exact immune strikes on tumors. For instance, in May 2023, AbbVie Inc., a U.S.-based biopharmaceutical company, secured FDA accelerated approval and debuted EPKINLY (epcoritamab-bysp). This targets adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma post-two or more prior systemic therapies, harnessing bispecific tech to summon T-cells for a focused lymphoma assault.

In March 2024, Johnson & Johnson, a US-based multinational corporation that develops and manufactures medical devices and pharmaceuticals, bought Ambrx for $2 billion. Through this acquisition, Johnson & Johnson seeks to enrich its oncology lineup with next-gen antibody-drug conjugates, especially for metastatic castration-resistant prostate cancer. Ambrx is a US-based biotechnology company that specializes in antibody drug conjugates.

Major companies operating in the cancer monoclonal antibodies market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Genzyme.

North America was the largest region in the cancer monoclonal antibodies market in 2025. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the cancer monoclonal antibodies market by raising the cost of imported biologics, laboratory reagents, and manufacturing equipment. Hospital oncology departments and research laboratories in regions such as North America and Europe, which depend heavily on imports, are most affected. This has led to increased treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local manufacturing, R&D investments, and the development of cost-optimized monoclonal antibody therapies.

The cancer monoclonal antibodies market research report is one of a series of new reports that provides cancer monoclonal antibodies market statistics, including cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the cancer monoclonal antibodies industry. This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer monoclonal antibodies are a class of laboratory-produced proteins designed to bind to specific targets in the body, such as antigens present on cancer cell surfaces. Each monoclonal antibody is engineered to recognize a single antigen, with multiple types available for different therapeutic purposes.

The main types of monoclonal antibody therapies for cancer include bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin is used to treat conditions such as wet age-related macular degeneration (AMD), diabetic eye complications, and other retinal disorders by being administered into the eye to slow vision loss. These therapies are applied in various cancers, including breast, blood, liver, brain, and colorectal cancers, and are used across hospitals and clinics, research laboratories, pharmacies, and other healthcare and research settings.

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.